BiomarkersHuman trial630 participants24 monthsCohort studyDeclared ties to: University of Colorado, Anthos Therapeutics, Arrowhead Pharmaceuticals and 62 more

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT

Journal of Clinical Lipidology

Lipid and ceramide metabolism
Lipoprotein
LPA
Cardiovascular disease
Hypertriglyceridemia
Humans

The paper

Michael J. Szarek, Deepak L. Bhatt, Michael J. Miller,

Eliot A. Brinton, Jean‐Claude Tardif, Christie Mitchell Ballantyne, Steven B. Ketchum, Armando Lira Pineda, Philippe Gabríel Steg, Terry A. Jacobson,

Richard Preston Mason

University of Colorado Anschutz · Elucida Research LLC

Journal of Clinical Lipidology · 2 Sep 2026

doi.org/10.1016/j.jacl.2026.08.020 PubMed 42749529

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT

The paper

Small HDL particle count is linked to lower mortality

Cumulative non-HDL cholesterol is linked to CVD risk

Social context predicts heart risks despite normal biomarkers

Mild caloric restriction accelerates atherosclerosis in mice

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT

The paper

More on Lipid and ceramide metabolism